Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. (RARE) Stock Competitors & Peer Comparison
See (RARE) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RARE | $29.52 | +0.54% | 2.8B | -5.39 | -$5.48 | N/A |
| VRTX | $397.46 | +0.79% | 101.9B | 28.25 | $14.07 | N/A |
| REGN | $598.16 | +1.21% | 62.3B | 15.09 | $39.66 | +0.44% |
| ALNY | $467.55 | +2.02% | 61.3B | -189.29 | -$2.47 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ARGX | $663.73 | +0.42% | 40.6B | 33.79 | $19.64 | N/A |
| BNTX | $110.77 | -0.48% | 26.6B | -66.33 | -$1.67 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| SMMT | $26.01 | +0.54% | 19.3B | -25.75 | -$1.01 | N/A |
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
Stock Comparison
RARE vs VRTX Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, VRTX has a market cap of 101.9B. Regarding current trading prices, RARE is priced at $29.52, while VRTX trades at $397.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas VRTX's P/E ratio is 28.25. In terms of profitability, RARE's ROE is -2.37%, compared to VRTX's ROE of +0.22%. Regarding short-term risk, RARE is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check VRTX's competition here
RARE vs REGN Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, REGN has a market cap of 62.3B. Regarding current trading prices, RARE is priced at $29.52, while REGN trades at $598.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas REGN's P/E ratio is 15.09. In terms of profitability, RARE's ROE is -2.37%, compared to REGN's ROE of +0.15%. Regarding short-term risk, RARE is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check REGN's competition here
RARE vs ALNY Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, ALNY has a market cap of 61.3B. Regarding current trading prices, RARE is priced at $29.52, while ALNY trades at $467.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas ALNY's P/E ratio is -189.29. In terms of profitability, RARE's ROE is -2.37%, compared to ALNY's ROE of -2.74%. Regarding short-term risk, RARE is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check ALNY's competition here
RARE vs SGEN Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, RARE is priced at $29.52, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas SGEN's P/E ratio is -57.19. In terms of profitability, RARE's ROE is -2.37%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, RARE is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check SGEN's competition here
RARE vs ARGX Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, ARGX has a market cap of 40.6B. Regarding current trading prices, RARE is priced at $29.52, while ARGX trades at $663.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas ARGX's P/E ratio is 33.79. In terms of profitability, RARE's ROE is -2.37%, compared to ARGX's ROE of +0.26%. Regarding short-term risk, RARE is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ARGX's competition here
RARE vs BNTX Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, BNTX has a market cap of 26.6B. Regarding current trading prices, RARE is priced at $29.52, while BNTX trades at $110.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas BNTX's P/E ratio is -66.33. In terms of profitability, RARE's ROE is -2.37%, compared to BNTX's ROE of -0.02%. Regarding short-term risk, RARE is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check BNTX's competition here
RARE vs BGNE Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, RARE is priced at $29.52, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas BGNE's P/E ratio is -22.55. In terms of profitability, RARE's ROE is -2.37%, compared to BGNE's ROE of -0.05%. Regarding short-term risk, RARE is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check BGNE's competition here
RARE vs SMMT Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, SMMT has a market cap of 19.3B. Regarding current trading prices, RARE is priced at $29.52, while SMMT trades at $26.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas SMMT's P/E ratio is -25.75. In terms of profitability, RARE's ROE is -2.37%, compared to SMMT's ROE of -2.09%. Regarding short-term risk, RARE is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check SMMT's competition here
RARE vs DNA-WT Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, RARE is priced at $29.52, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, RARE's ROE is -2.37%, compared to DNA-WT's ROE of -0.45%. Regarding short-term risk, RARE is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check DNA-WT's competition here
RARE vs INCY Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, INCY has a market cap of 16.9B. Regarding current trading prices, RARE is priced at $29.52, while INCY trades at $86.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas INCY's P/E ratio is 20.46. In terms of profitability, RARE's ROE is -2.37%, compared to INCY's ROE of +0.24%. Regarding short-term risk, RARE is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check INCY's competition here
RARE vs RPRX Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, RPRX has a market cap of 15.7B. Regarding current trading prices, RARE is priced at $29.52, while RPRX trades at $36.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas RPRX's P/E ratio is 15.86. In terms of profitability, RARE's ROE is -2.37%, compared to RPRX's ROE of +0.15%. Regarding short-term risk, RARE is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check RPRX's competition here
RARE vs GMAB Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, GMAB has a market cap of 15.4B. Regarding current trading prices, RARE is priced at $29.52, while GMAB trades at $24.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas GMAB's P/E ratio is 12.65. In terms of profitability, RARE's ROE is -2.37%, compared to GMAB's ROE of +0.28%. Regarding short-term risk, RARE is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check GMAB's competition here
RARE vs UTHR Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, UTHR has a market cap of 14.1B. Regarding current trading prices, RARE is priced at $29.52, while UTHR trades at $310.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas UTHR's P/E ratio is 12.13. In terms of profitability, RARE's ROE is -2.37%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, RARE is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check UTHR's competition here
RARE vs KRTX Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, RARE is priced at $29.52, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas KRTX's P/E ratio is -28.09. In terms of profitability, RARE's ROE is -2.37%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, RARE is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check KRTX's competition here
RARE vs ASND Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, ASND has a market cap of 11.7B. Regarding current trading prices, RARE is priced at $29.52, while ASND trades at $192.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas ASND's P/E ratio is -36.52. In terms of profitability, RARE's ROE is -2.37%, compared to ASND's ROE of +1.52%. Regarding short-term risk, RARE is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check ASND's competition here
RARE vs BMRN Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, BMRN has a market cap of 11.2B. Regarding current trading prices, RARE is priced at $29.52, while BMRN trades at $58.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas BMRN's P/E ratio is 17.13. In terms of profitability, RARE's ROE is -2.37%, compared to BMRN's ROE of +0.11%. Regarding short-term risk, RARE is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check BMRN's competition here
RARE vs EXEL Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, EXEL has a market cap of 10.4B. Regarding current trading prices, RARE is priced at $29.52, while EXEL trades at $38.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas EXEL's P/E ratio is 18.61. In terms of profitability, RARE's ROE is -2.37%, compared to EXEL's ROE of +0.28%. Regarding short-term risk, RARE is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check EXEL's competition here
RARE vs MRNA Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, MRNA has a market cap of 10.2B. Regarding current trading prices, RARE is priced at $29.52, while MRNA trades at $26.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas MRNA's P/E ratio is -3.49. In terms of profitability, RARE's ROE is -2.37%, compared to MRNA's ROE of -0.27%. Regarding short-term risk, RARE is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check MRNA's competition here
RARE vs BBIO Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, BBIO has a market cap of 9.6B. Regarding current trading prices, RARE is priced at $29.52, while BBIO trades at $50.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas BBIO's P/E ratio is -12.16. In terms of profitability, RARE's ROE is -2.37%, compared to BBIO's ROE of +0.51%. Regarding short-term risk, RARE is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check BBIO's competition here
RARE vs RXDX Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, RARE is priced at $29.52, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas RXDX's P/E ratio is -56.47. In terms of profitability, RARE's ROE is -2.37%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, RARE is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check RXDX's competition here
RARE vs MDGL Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, MDGL has a market cap of 9.1B. Regarding current trading prices, RARE is priced at $29.52, while MDGL trades at $407.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas MDGL's P/E ratio is -32.21. In terms of profitability, RARE's ROE is -2.37%, compared to MDGL's ROE of -0.38%. Regarding short-term risk, RARE is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check MDGL's competition here
RARE vs VRNA Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, VRNA has a market cap of 9B. Regarding current trading prices, RARE is priced at $29.52, while VRNA trades at $105.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas VRNA's P/E ratio is -100.43. In terms of profitability, RARE's ROE is -2.37%, compared to VRNA's ROE of -0.39%. Regarding short-term risk, RARE is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check VRNA's competition here
RARE vs IMGN Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, RARE is priced at $29.52, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas IMGN's P/E ratio is -111.55. In terms of profitability, RARE's ROE is -2.37%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, RARE is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check IMGN's competition here
RARE vs TECH Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, TECH has a market cap of 8.5B. Regarding current trading prices, RARE is priced at $29.52, while TECH trades at $54.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas TECH's P/E ratio is 117.39. In terms of profitability, RARE's ROE is -2.37%, compared to TECH's ROE of +0.06%. Regarding short-term risk, RARE is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check TECH's competition here
RARE vs HALO Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, HALO has a market cap of 8.4B. Regarding current trading prices, RARE is priced at $29.52, while HALO trades at $71.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas HALO's P/E ratio is 16.39. In terms of profitability, RARE's ROE is -2.37%, compared to HALO's ROE of +1.37%. Regarding short-term risk, RARE is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check HALO's competition here
RARE vs BPMC Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, RARE is priced at $29.52, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas BPMC's P/E ratio is -51.58. In terms of profitability, RARE's ROE is -2.37%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, RARE is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check BPMC's competition here
RARE vs CERE Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, RARE is priced at $29.52, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas CERE's P/E ratio is -16.47. In terms of profitability, RARE's ROE is -2.37%, compared to CERE's ROE of -0.72%. Regarding short-term risk, RARE is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check CERE's competition here
RARE vs ROIV Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, ROIV has a market cap of 8.1B. Regarding current trading prices, RARE is priced at $29.52, while ROIV trades at $11.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas ROIV's P/E ratio is -10.83. In terms of profitability, RARE's ROE is -2.37%, compared to ROIV's ROE of -0.10%. Regarding short-term risk, RARE is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ROIV's competition here
RARE vs ROIVW Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, RARE is priced at $29.52, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, RARE's ROE is -2.37%, compared to ROIVW's ROE of -0.10%. Regarding short-term risk, RARE is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check ROIVW's competition here
RARE vs CORT Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, CORT has a market cap of 7.5B. Regarding current trading prices, RARE is priced at $29.52, while CORT trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas CORT's P/E ratio is 63.38. In terms of profitability, RARE's ROE is -2.37%, compared to CORT's ROE of +0.20%. Regarding short-term risk, RARE is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check CORT's competition here
RARE vs JAZZ Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, JAZZ has a market cap of 7.3B. Regarding current trading prices, RARE is priced at $29.52, while JAZZ trades at $120.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas JAZZ's P/E ratio is -17.24. In terms of profitability, RARE's ROE is -2.37%, compared to JAZZ's ROE of -0.10%. Regarding short-term risk, RARE is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check JAZZ's competition here
RARE vs IONS Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, IONS has a market cap of 6.9B. Regarding current trading prices, RARE is priced at $29.52, while IONS trades at $43.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas IONS's P/E ratio is -24.57. In terms of profitability, RARE's ROE is -2.37%, compared to IONS's ROE of -0.45%. Regarding short-term risk, RARE is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check IONS's competition here
RARE vs RVMD Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, RVMD has a market cap of 6.8B. Regarding current trading prices, RARE is priced at $29.52, while RVMD trades at $36.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas RVMD's P/E ratio is -8.07. In terms of profitability, RARE's ROE is -2.37%, compared to RVMD's ROE of -0.42%. Regarding short-term risk, RARE is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check RVMD's competition here
RARE vs RYTM Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, RARE is priced at $29.52, while RYTM trades at $101.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas RYTM's P/E ratio is -33.78. In terms of profitability, RARE's ROE is -2.37%, compared to RYTM's ROE of -1.55%. Regarding short-term risk, RARE is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check RYTM's competition here
RARE vs RETA Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, RARE is priced at $29.52, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas RETA's P/E ratio is -66.29. In terms of profitability, RARE's ROE is -2.37%, compared to RETA's ROE of +0.47%. Regarding short-term risk, RARE is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check RETA's competition here
RARE vs AXSM Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, AXSM has a market cap of 5.8B. Regarding current trading prices, RARE is priced at $29.52, while AXSM trades at $117.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas AXSM's P/E ratio is -23.15. In terms of profitability, RARE's ROE is -2.37%, compared to AXSM's ROE of -3.58%. Regarding short-term risk, RARE is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check AXSM's competition here
RARE vs RNA Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, RNA has a market cap of 5.7B. Regarding current trading prices, RARE is priced at $29.52, while RNA trades at $44.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas RNA's P/E ratio is -12.54. In terms of profitability, RARE's ROE is -2.37%, compared to RNA's ROE of -0.33%. Regarding short-term risk, RARE is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check RNA's competition here
RARE vs ABVX Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, ABVX has a market cap of 5.6B. Regarding current trading prices, RARE is priced at $29.52, while ABVX trades at $74.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas ABVX's P/E ratio is -21.64. In terms of profitability, RARE's ROE is -2.37%, compared to ABVX's ROE of -1.62%. Regarding short-term risk, RARE is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check ABVX's competition here
RARE vs ABCM Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, RARE is priced at $29.52, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, RARE's ROE is -2.37%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, RARE is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ABCM's competition here
RARE vs ISEE Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, RARE is priced at $29.52, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas ISEE's P/E ratio is -22.44. In terms of profitability, RARE's ROE is -2.37%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, RARE is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ISEE's competition here
RARE vs NUVL Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, NUVL has a market cap of 5.3B. Regarding current trading prices, RARE is priced at $29.52, while NUVL trades at $73.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas NUVL's P/E ratio is -14.97. In terms of profitability, RARE's ROE is -2.37%, compared to NUVL's ROE of -0.33%. Regarding short-term risk, RARE is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check NUVL's competition here
RARE vs MRUS Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, MRUS has a market cap of 5B. Regarding current trading prices, RARE is priced at $29.52, while MRUS trades at $66.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas MRUS's P/E ratio is -11.94. In terms of profitability, RARE's ROE is -2.37%, compared to MRUS's ROE of -0.55%. Regarding short-term risk, RARE is less volatile compared to MRUS. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check MRUS's competition here
RARE vs CRSP Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, CRSP has a market cap of 4.8B. Regarding current trading prices, RARE is priced at $29.52, while CRSP trades at $52.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas CRSP's P/E ratio is -9.78. In terms of profitability, RARE's ROE is -2.37%, compared to CRSP's ROE of -0.25%. Regarding short-term risk, RARE is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check CRSP's competition here
RARE vs ALKS Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, ALKS has a market cap of 4.8B. Regarding current trading prices, RARE is priced at $29.52, while ALKS trades at $29.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas ALKS's P/E ratio is 14.04. In terms of profitability, RARE's ROE is -2.37%, compared to ALKS's ROE of +0.24%. Regarding short-term risk, RARE is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ALKS's competition here
RARE vs TGTX Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, TGTX has a market cap of 4.6B. Regarding current trading prices, RARE is priced at $29.52, while TGTX trades at $28.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas TGTX's P/E ratio is 75.71. In terms of profitability, RARE's ROE is -2.37%, compared to TGTX's ROE of +0.29%. Regarding short-term risk, RARE is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check TGTX's competition here
RARE vs CYTK Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, CYTK has a market cap of 4.6B. Regarding current trading prices, RARE is priced at $29.52, while CYTK trades at $38.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas CYTK's P/E ratio is -7.43. In terms of profitability, RARE's ROE is -2.37%, compared to CYTK's ROE of +3.09%. Regarding short-term risk, RARE is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check CYTK's competition here
RARE vs AAPG Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, AAPG has a market cap of 4.6B. Regarding current trading prices, RARE is priced at $29.52, while AAPG trades at $47.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas AAPG's P/E ratio is -65.53. In terms of profitability, RARE's ROE is -2.37%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, RARE is less volatile compared to AAPG. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check AAPG's competition here
RARE vs ALPN Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, RARE is priced at $29.52, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas ALPN's P/E ratio is -101.52. In terms of profitability, RARE's ROE is -2.37%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, RARE is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ALPN's competition here
RARE vs KRYS Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, KRYS has a market cap of 4.2B. Regarding current trading prices, RARE is priced at $29.52, while KRYS trades at $145.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas KRYS's P/E ratio is 29.61. In terms of profitability, RARE's ROE is -2.37%, compared to KRYS's ROE of +0.15%. Regarding short-term risk, RARE is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check KRYS's competition here
RARE vs OPT Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, RARE is priced at $29.52, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas OPT's P/E ratio is -1.52. In terms of profitability, RARE's ROE is -2.37%, compared to OPT's ROE of +2.60%. Regarding short-term risk, RARE is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check OPT's competition here
RARE vs ACAD Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, ACAD has a market cap of 4.2B. Regarding current trading prices, RARE is priced at $29.52, while ACAD trades at $24.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas ACAD's P/E ratio is 18.64. In terms of profitability, RARE's ROE is -2.37%, compared to ACAD's ROE of +0.31%. Regarding short-term risk, RARE is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ACAD's competition here
RARE vs PCVX Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, PCVX has a market cap of 4.1B. Regarding current trading prices, RARE is priced at $29.52, while PCVX trades at $31.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas PCVX's P/E ratio is -7.76. In terms of profitability, RARE's ROE is -2.37%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, RARE is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check PCVX's competition here
RARE vs MRTX Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, RARE is priced at $29.52, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas MRTX's P/E ratio is -4.82. In terms of profitability, RARE's ROE is -2.37%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, RARE is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check MRTX's competition here
RARE vs TLX Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, TLX has a market cap of 4.1B. Regarding current trading prices, RARE is priced at $29.52, while TLX trades at $12.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas TLX's P/E ratio is 134.33. In terms of profitability, RARE's ROE is -2.37%, compared to TLX's ROE of +0.10%. Regarding short-term risk, RARE is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check TLX's competition here
RARE vs ADMA Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, ADMA has a market cap of 4.1B. Regarding current trading prices, RARE is priced at $29.52, while ADMA trades at $17.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas ADMA's P/E ratio is 20.12. In terms of profitability, RARE's ROE is -2.37%, compared to ADMA's ROE of +0.62%. Regarding short-term risk, RARE is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ADMA's competition here
RARE vs ACLX Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, ACLX has a market cap of 4B. Regarding current trading prices, RARE is priced at $29.52, while ACLX trades at $71.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas ACLX's P/E ratio is -21.05. In terms of profitability, RARE's ROE is -2.37%, compared to ACLX's ROE of -0.43%. Regarding short-term risk, RARE is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check ACLX's competition here
RARE vs PTCT Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, PTCT has a market cap of 3.9B. Regarding current trading prices, RARE is priced at $29.52, while PTCT trades at $48.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas PTCT's P/E ratio is 6.94. In terms of profitability, RARE's ROE is -2.37%, compared to PTCT's ROE of -0.99%. Regarding short-term risk, RARE is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check PTCT's competition here
RARE vs AKRO Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, AKRO has a market cap of 3.9B. Regarding current trading prices, RARE is priced at $29.52, while AKRO trades at $48.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas AKRO's P/E ratio is -12.67. In terms of profitability, RARE's ROE is -2.37%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, RARE is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check AKRO's competition here
RARE vs RYZB Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, RARE is priced at $29.52, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas RYZB's P/E ratio is -57.86. In terms of profitability, RARE's ROE is -2.37%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, RARE is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check RYZB's competition here
RARE vs ZLAB Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, ZLAB has a market cap of 3.7B. Regarding current trading prices, RARE is priced at $29.52, while ZLAB trades at $33.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas ZLAB's P/E ratio is -16.99. In terms of profitability, RARE's ROE is -2.37%, compared to ZLAB's ROE of -0.27%. Regarding short-term risk, RARE is less volatile compared to ZLAB. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check ZLAB's competition here
RARE vs CBAY Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, RARE is priced at $29.52, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas CBAY's P/E ratio is -32.81. In terms of profitability, RARE's ROE is -2.37%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, RARE is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check CBAY's competition here
RARE vs SLNO Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, SLNO has a market cap of 3.7B. Regarding current trading prices, RARE is priced at $29.52, while SLNO trades at $69.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas SLNO's P/E ratio is -16.54. In terms of profitability, RARE's ROE is -2.37%, compared to SLNO's ROE of -0.74%. Regarding short-term risk, RARE is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check SLNO's competition here
RARE vs SWTX Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, RARE is priced at $29.52, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas SWTX's P/E ratio is -13.78. In terms of profitability, RARE's ROE is -2.37%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, RARE is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check SWTX's competition here
RARE vs APLS Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, APLS has a market cap of 3.5B. Regarding current trading prices, RARE is priced at $29.52, while APLS trades at $27.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas APLS's P/E ratio is -15.09. In terms of profitability, RARE's ROE is -2.37%, compared to APLS's ROE of -1.16%. Regarding short-term risk, RARE is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check APLS's competition here
RARE vs PTGX Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, PTGX has a market cap of 3.5B. Regarding current trading prices, RARE is priced at $29.52, while PTGX trades at $56.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas PTGX's P/E ratio is 76.77. In terms of profitability, RARE's ROE is -2.37%, compared to PTGX's ROE of +0.08%. Regarding short-term risk, RARE is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check PTGX's competition here
RARE vs MIRM Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, MIRM has a market cap of 3.5B. Regarding current trading prices, RARE is priced at $29.52, while MIRM trades at $69.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas MIRM's P/E ratio is -57.07. In terms of profitability, RARE's ROE is -2.37%, compared to MIRM's ROE of -0.25%. Regarding short-term risk, RARE is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check MIRM's competition here
RARE vs MTSR Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, MTSR has a market cap of 3.4B. Regarding current trading prices, RARE is priced at $29.52, while MTSR trades at $32.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas MTSR's P/E ratio is -11.16. In terms of profitability, RARE's ROE is -2.37%, compared to MTSR's ROE of -0.90%. Regarding short-term risk, RARE is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check MTSR's competition here
RARE vs MLTX Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, MLTX has a market cap of 3.4B. Regarding current trading prices, RARE is priced at $29.52, while MLTX trades at $54.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas MLTX's P/E ratio is -19.42. In terms of profitability, RARE's ROE is -2.37%, compared to MLTX's ROE of -0.42%. Regarding short-term risk, RARE is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check MLTX's competition here
RARE vs SRRK Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, SRRK has a market cap of 3.3B. Regarding current trading prices, RARE is priced at $29.52, while SRRK trades at $34.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas SRRK's P/E ratio is -11.85. In terms of profitability, RARE's ROE is -2.37%, compared to SRRK's ROE of -1.27%. Regarding short-term risk, RARE is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check SRRK's competition here
RARE vs LEGN Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, LEGN has a market cap of 3.3B. Regarding current trading prices, RARE is priced at $29.52, while LEGN trades at $35.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas LEGN's P/E ratio is -19.96. In terms of profitability, RARE's ROE is -2.37%, compared to LEGN's ROE of -0.31%. Regarding short-term risk, RARE is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check LEGN's competition here
RARE vs LGND Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, LGND has a market cap of 3.1B. Regarding current trading prices, RARE is priced at $29.52, while LGND trades at $157.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas LGND's P/E ratio is -38.94. In terms of profitability, RARE's ROE is -2.37%, compared to LGND's ROE of -0.09%. Regarding short-term risk, RARE is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check LGND's competition here
RARE vs KYMR Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, KYMR has a market cap of 3B. Regarding current trading prices, RARE is priced at $29.52, while KYMR trades at $42.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas KYMR's P/E ratio is -12.20. In terms of profitability, RARE's ROE is -2.37%, compared to KYMR's ROE of -0.32%. Regarding short-term risk, RARE is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check KYMR's competition here
RARE vs XENE Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, XENE has a market cap of 2.9B. Regarding current trading prices, RARE is priced at $29.52, while XENE trades at $38.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas XENE's P/E ratio is -10.75. In terms of profitability, RARE's ROE is -2.37%, compared to XENE's ROE of -0.39%. Regarding short-term risk, RARE is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check XENE's competition here
RARE vs VKTX Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, VKTX has a market cap of 2.9B. Regarding current trading prices, RARE is priced at $29.52, while VKTX trades at $25.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas VKTX's P/E ratio is -16.66. In terms of profitability, RARE's ROE is -2.37%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, RARE is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check VKTX's competition here
RARE vs ARWR Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, ARWR has a market cap of 2.9B. Regarding current trading prices, RARE is priced at $29.52, while ARWR trades at $20.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas ARWR's P/E ratio is -17.29. In terms of profitability, RARE's ROE is -2.37%, compared to ARWR's ROE of -0.41%. Regarding short-term risk, RARE is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check ARWR's competition here
RARE vs MORF Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, RARE is priced at $29.52, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas MORF's P/E ratio is -14.88. In terms of profitability, RARE's ROE is -2.37%, compared to MORF's ROE of -0.16%. Regarding short-term risk, RARE is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check MORF's competition here
RARE vs MOR Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, RARE is priced at $29.52, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas MOR's P/E ratio is -12.64. In terms of profitability, RARE's ROE is -2.37%, compared to MOR's ROE of -1.84%. Regarding short-term risk, RARE is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check MOR's competition here
RARE vs CRNX Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, CRNX has a market cap of 2.8B. Regarding current trading prices, RARE is priced at $29.52, while CRNX trades at $29.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas CRNX's P/E ratio is -7.17. In terms of profitability, RARE's ROE is -2.37%, compared to CRNX's ROE of -0.32%. Regarding short-term risk, RARE is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check CRNX's competition here
RARE vs NAMS Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, NAMS has a market cap of 2.8B. Regarding current trading prices, RARE is priced at $29.52, while NAMS trades at $24.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas NAMS's P/E ratio is -15.37. In terms of profitability, RARE's ROE is -2.37%, compared to NAMS's ROE of -0.25%. Regarding short-term risk, RARE is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check NAMS's competition here
RARE vs KDNY Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, RARE is priced at $29.52, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas KDNY's P/E ratio is -12.47. In terms of profitability, RARE's ROE is -2.37%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, RARE is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check KDNY's competition here
RARE vs MYOV Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, RARE is priced at $29.52, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas MYOV's P/E ratio is -14.05. In terms of profitability, RARE's ROE is -2.37%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, RARE is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check MYOV's competition here
RARE vs IMVT Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, IMVT has a market cap of 2.6B. Regarding current trading prices, RARE is priced at $29.52, while IMVT trades at $14.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas IMVT's P/E ratio is -5.23. In terms of profitability, RARE's ROE is -2.37%, compared to IMVT's ROE of -0.84%. Regarding short-term risk, RARE is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check IMVT's competition here
RARE vs CPRX Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, CPRX has a market cap of 2.5B. Regarding current trading prices, RARE is priced at $29.52, while CPRX trades at $20.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas CPRX's P/E ratio is 12.46. In terms of profitability, RARE's ROE is -2.37%, compared to CPRX's ROE of +0.27%. Regarding short-term risk, RARE is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check CPRX's competition here
RARE vs KNSA Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, KNSA has a market cap of 2.5B. Regarding current trading prices, RARE is priced at $29.52, while KNSA trades at $33.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas KNSA's P/E ratio is 671.60. In terms of profitability, RARE's ROE is -2.37%, compared to KNSA's ROE of +0.01%. Regarding short-term risk, RARE is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check KNSA's competition here
RARE vs TARS Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, TARS has a market cap of 2.4B. Regarding current trading prices, RARE is priced at $29.52, while TARS trades at $56.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas TARS's P/E ratio is -24.69. In terms of profitability, RARE's ROE is -2.37%, compared to TARS's ROE of -0.32%. Regarding short-term risk, RARE is less volatile compared to TARS. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check TARS's competition here
RARE vs PRVB Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, RARE is priced at $29.52, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas PRVB's P/E ratio is -16.43. In terms of profitability, RARE's ROE is -2.37%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, RARE is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check PRVB's competition here
RARE vs LQDA Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, LQDA has a market cap of 2.4B. Regarding current trading prices, RARE is priced at $29.52, while LQDA trades at $27.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas LQDA's P/E ratio is -15.00. In terms of profitability, RARE's ROE is -2.37%, compared to LQDA's ROE of -1.58%. Regarding short-term risk, RARE is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check LQDA's competition here
RARE vs CNTA Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, CNTA has a market cap of 2.3B. Regarding current trading prices, RARE is priced at $29.52, while CNTA trades at $17.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas CNTA's P/E ratio is -9.48. In terms of profitability, RARE's ROE is -2.37%, compared to CNTA's ROE of -0.56%. Regarding short-term risk, RARE is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check CNTA's competition here
RARE vs FOLD Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, FOLD has a market cap of 2.3B. Regarding current trading prices, RARE is priced at $29.52, while FOLD trades at $7.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas FOLD's P/E ratio is -63.33. In terms of profitability, RARE's ROE is -2.37%, compared to FOLD's ROE of -0.20%. Regarding short-term risk, RARE is less volatile compared to FOLD. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check FOLD's competition here
RARE vs LBPH Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, RARE is priced at $29.52, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas LBPH's P/E ratio is -26.66. In terms of profitability, RARE's ROE is -2.37%, compared to LBPH's ROE of -0.21%. Regarding short-term risk, RARE is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check LBPH's competition here
RARE vs VCYT Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, VCYT has a market cap of 2.3B. Regarding current trading prices, RARE is priced at $29.52, while VCYT trades at $29.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas VCYT's P/E ratio is 86.56. In terms of profitability, RARE's ROE is -2.37%, compared to VCYT's ROE of +0.02%. Regarding short-term risk, RARE is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check VCYT's competition here
RARE vs DICE Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, RARE is priced at $29.52, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas DICE's P/E ratio is -21.91. In terms of profitability, RARE's ROE is -2.37%, compared to DICE's ROE of +0.56%. Regarding short-term risk, RARE is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check DICE's competition here
RARE vs DNLI Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, DNLI has a market cap of 2.2B. Regarding current trading prices, RARE is priced at $29.52, while DNLI trades at $15.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas DNLI's P/E ratio is -5.42. In terms of profitability, RARE's ROE is -2.37%, compared to DNLI's ROE of -0.41%. Regarding short-term risk, RARE is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check DNLI's competition here
RARE vs AGIO Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, AGIO has a market cap of 2.2B. Regarding current trading prices, RARE is priced at $29.52, while AGIO trades at $38.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas AGIO's P/E ratio is 3.38. In terms of profitability, RARE's ROE is -2.37%, compared to AGIO's ROE of +0.43%. Regarding short-term risk, RARE is less volatile compared to AGIO. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check AGIO's competition here
RARE vs APGE Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, APGE has a market cap of 2.2B. Regarding current trading prices, RARE is priced at $29.52, while APGE trades at $36.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas APGE's P/E ratio is -8.78. In terms of profitability, RARE's ROE is -2.37%, compared to APGE's ROE of -0.23%. Regarding short-term risk, RARE is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check APGE's competition here
RARE vs IDYA Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, IDYA has a market cap of 2.2B. Regarding current trading prices, RARE is priced at $29.52, while IDYA trades at $24.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas IDYA's P/E ratio is -6.41. In terms of profitability, RARE's ROE is -2.37%, compared to IDYA's ROE of -0.31%. Regarding short-term risk, RARE is less volatile compared to IDYA. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check IDYA's competition here
RARE vs CALT Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, RARE is priced at $29.52, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas CALT's P/E ratio is -22.73. In terms of profitability, RARE's ROE is -2.37%, compared to CALT's ROE of -1.67%. Regarding short-term risk, RARE is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check CALT's competition here
RARE vs HRMY Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, HRMY has a market cap of 2.1B. Regarding current trading prices, RARE is priced at $29.52, while HRMY trades at $37.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas HRMY's P/E ratio is 12.03. In terms of profitability, RARE's ROE is -2.37%, compared to HRMY's ROE of +0.26%. Regarding short-term risk, RARE is less volatile compared to HRMY. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check HRMY's competition here
RARE vs CELC Comparison August 2025
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.8B. In comparison, CELC has a market cap of 2.1B. Regarding current trading prices, RARE is priced at $29.52, while CELC trades at $50.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -5.39, whereas CELC's P/E ratio is -14.52. In terms of profitability, RARE's ROE is -2.37%, compared to CELC's ROE of -1.50%. Regarding short-term risk, RARE is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check CELC's competition here